Search tips
Search criteria 


Logo of annrheumdAnnals of the Rheumatic DiseasesVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Ann Rheum Dis. 2007 December; 66(12): 1661–1668.
Published online 2007 May 15. doi:  10.1136/ard.2007.070482
PMCID: PMC2095330

Nucleosomes possess a high affinity for glomerular laminin and collagen IV and bind nephritogenic antibodies in murine lupus‐like nephritis



Lupus nephritis is closely associated with in vivo autoantibody‐binding to glomerular membrane‐associated electron‐dense structures (EDS). The biochemical nature and cellular origin of EDS are controversial, and definitive characterisation needs to be performed.


By using the terminal transferase biotin‐dUTP nick end‐labelling (TUNEL) assay at the electron microscopic level, we have traced extracellular chromatin within the glomerular basement membranes of nephritic (NZB×NZW)F1 mice. The TUNEL assay was subsequently used in combination with standard immune electron microscopy (IEM). To analyse why chromatin particles associate with membranes, we determined the affinity of nucleosomes and DNA for glomerular laminin, collagen IV and the mesangial matrix proteoglycan perlecan by surface plasmon resonance.


This intra‐assay colocalisation TUNEL IEM demonstrated that autoantibodies fully colocalised with extracellular TUNEL‐positive chromatin observed as EDS in glomerular membranes, similar to results obtained by the same technique applied to human lupus nephritis. Most importantly, these data validate the murine variant of lupus nephritis as a model to study origin of extracellular chromatin as a key element in human lupus nephritis. Kinetic analyses demonstrated that nucleosomes had a high affinity for collagen IV and laminin, but not for perlecan.


Collectively, these results provide firm evidence that dominant target structures for nephritogenic autoantibodies are constituted by TUNEL‐positive chromatin associated with glomerular capillary and mesangial matrix membranes at high affinity.

Systemic lupus erythematosus (SLE) is characterised by production of antibodies to DNA and nucleosomes. These are central in both a diagnostic and a pathogenic context.1,2,3,4 Of the organ manifestations in SLE, renal involvement is one of the most serious complications.5

Firm descriptions of glomerular target structures for nephritogenic autoantibodies are, although studied over decades, inconsistent. Two hypotheses dominate this field. Either nephritogenic autoantibodies recognise externalised nucleosomes associated with glomerular membranes,6,7,8 or they cross‐react with non‐nucleosomal glomerular antigens like laminin, collagen or α‐actinin.9,10,11,12

Recently, we have analysed murine nephritic kidneys by morphological and immunological assays, including immune electron microscopy (IEM) and colocalisation IEM.13,14 With these techniques, we have observed antibody‐binding in vivo confined to electron dense structures (EDS) in glomerular membranes.14 These in vivo‐bound autoantibodies fully colocalised with experimental monoclonal antibodies against dsDNA, histones or against transcription factors.14

Since the experimental monoclonal antibodies (mAbs) used in colocalisation IEM may be cross‐reactive,9,10,11,12,15 it was decided to implement an independent DNA‐specific assay, like the terminal deoxynucleotidyl transferase biotin‐dUTP nick end labelling (TUNEL) assay, to describe the nature of glomerular membrane‐associated EDS. Furthermore, it became important to establish why such structures associate with glomerular membranes, to develop treatment modalities to avoid this potentially pathogenic association.

Data from the present analyses demonstrate that (1) autoantibodies are exclusively present in structures described 20–30 years ago as glomerular, membrane‐associated EDS,16,17,18 (2) the EDS contain TUNEL‐positive DNA that colocalise perfectly with in vivo‐bound antibodies and (3) nucleosomes bind renal capillary and mesangial matrix membrane collagen IV and laminin at high affinity. Perlecan, a glomerular mesangial matrix heparan sulfate proteoglycan (HSPG), did not bind nucleosomes in these experiments. From the present results, we revitalise the impact of nucleosomes and antinucleosome antibodies in lupus nephritis.

Material and methods

Kidney preparation, antigens and antibodies

Kidneys from BALB/c and B/W mice (Harlan, Bicester, UK) were fixed in 8% depolymerised paraformaldehyde and epoxy‐embedded (for TEM), or frozen in nitrogen (for IEM and TUNEL‐IEM) as described previously.14,19 Sera were stored at −20°C until use. The project was approved by The Norwegian Ethical and Welfare Board for Research Animals, and treatment and care of the mice were in accordance with institutional guidelines.

Laminin was purchased from Biomedical Technologies (Stroughton, MA) and collagen IV from BD Biosciences (San Jose, CA). HSPG was obtained from Sigma‐Aldrich (St. Louis, MO) and contained 460 μg of HS per 900 μg of core protein. Mass spectrometry analysis identified the HSPG to be perlecan (see below). This is in agreement with the HSPG produced in Engelbreth–Holm–Swarm mouse sarcoma cell.20 Calf thymus dsDNA was obtained from Sigma‐Aldrich, and mouse genomic dsDNA obtained from Calbiochem (Bad Soden, Germany). Antibodies to renal laminin were from Sigma‐Aldrich, to collagen IV from MD Biosciences (St. Paul, MN), and to perlecan from Upstate Biotechnology (Lake Placid, NY). The anti‐DNA 163p77 mAb was provided by Dr Tony Marion (University of Tennessee Health Science Center, Memphis, TN).

Nucleosome preparation

Stripped nucleosomes (SN), devoid of H1 and non‐histone proteins, were kindly provided by Dr Burlingame (INOVA Diagnostics, San Diego, CA). Nucleosomes were prepared from a murine fibroblast cell line and characterised as described previously.21,22 SN was shown to contain the core histones H2A, H2B, H3 and H4, while Nuc contained all histone classes and several non‐histone proteins. Both had DNA with a size distribution from 200 bp to several thousand bp (see fig 3C3C for details).

figure ar70482.f3
Figure 3 Surface plasmon resonance (SPR) analyses of binding of nucleosomes to glomerular membrane structures. Sensorgrams are presented for binding analyses of nucleosomes (Nuc), stripped nucleosomes (SN) and DNA (A) or antibodies (B) at different ...


Serum antibodies were detected by ELISA exactly as described in detail,4,14,23,24 using microtitre plates (Nunc MaxiSorp; Nunc, Copenhagen, Denmark) coated with nucleosomes (10 μg/ml as DNA) or calf thymus DNA (10 μg/ml).

Immune electron microscopy (IEM) and colocalisation IEM

Ultra‐thin cryosections of glomeruli from BALB/c or nephritic B/W mice were prepared as described.13,19 In vivo‐bound autoantibodies were detected by incubating the sections with rabbit antimouse (RaM) IgG antibodies followed by protein A‐5nm gold conjugate (PAG‐5nm). This procedure represents the IEM. For colocalisation IEM, the sections were then blocked with glutaraldehyde and glycine, and further incubated with the anti‐DNA 163p77 monoclonal antibody (mAb), or an antilaminin β2 antibody, followed by incubation with RaM IgG and subsequently with PAG‐10nm.14 Micrographs were taken at ×40 000 magnification using a JEM‐1010 transmission electron microscope (Jeol, Tokyo)

Colocalisation TUNEL IEM assay

Extracellular chromatin was detected by an in situ end‐labelling assay according to standard protocols with minor modifications.25 In short, ultra‐thin renal cryosections were incubated in terminal deoxynucleotidyl transferase (TdT) reaction buffer (RB, 25 mM Tris‐HCl, 200 mM potassium cacodylate, 25 μg/ml BSA, 1 mM CoCl2, pH 6.6) for 5 min, followed by a 60‐min incubation at 37°C with 400 U of recombinant TdT (Roche Applied Science) in TdT‐RB supplemented with 40 μM biotin‐16‐dUTP, in a humid chamber (Hybrite, Vysis, Abbot Molecular, Des Plaines, IL). Positive control sections were incubated with 3 U/ml DNase I in 40 mM Tris, 6 mM MgCl2, pH 7.5, for 10 min at R.T. The reaction was stopped with 10 mM Tris‐HCl, 1 mM EDTA prior to the TUNEL assay. Negative control sections were incubated in RB supplemented with biotinylated dUTP in the absence of TdT. Subsequently, the sections were incubated for 15 min in 1% fish skin gelatin (FSG). At this stage, the sections were incubated with RaM IgG antibodies for 20 min at room temperature to trace in vivo‐bound autoantibodies, followed by incubation with PAG‐5nm. The sections were then blocked with glutaraldehyde and glycine. Incorporated biotinylated nucleotides were labelled with a rabbit antibiotin antibody for 20 min followed by PAG‐10nm. The sections were washed in PBS between all incubations and finally contrasted with uranyl acetate in methylcellulose, and examined using the JEM‐1010 transmission electron microscope.

Surface plasmon resonance (SPR) analyses

SPR analyses were performed using the Biacore T100 system. Collagen IV, laminin and perlecan proteins were immobilised according to the manufacturer's instructions. Dextran (CM5) and Streptavidin (SA series S) coated sensor chips, Amine coupling kit, running buffer 10×HBS‐EP+, immobilisation buffers and regeneration solutions were obtained from Biacore (Uppsala, Sweden).

In pilot experiments, laminin and collagen IV were effectively immobilised on CM5 chips, while perlecan did not bind to this chip, but bound SA chips after biotinylation (data not shown). Collagen IV and laminin (20 μg/ml each) were immobilised on the surface of individual CM5 chips a flow rate of 5 μl/min, or coimmobilised (50 μg/ml total protein) on one CM5 chip. Immobilisation of collagen IV, laminin and collagen IV/laminin was stopped at 6000RU, 5600RU and 11 400RU, respectively. After immobilisation, CM5 chips were inactivated with 1 M ethanolamine‐HCl. The reference flow cell for each ligand was treated in the same manner but without the protein. Perlecan was biotinylated using ProtoArray Mini‐Biotinylation Kit (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. The biotinylated perlecan, 40 μg/ml in running buffer, was immobilised on an SA chip at a flow rate of 10 μl/min. The maximum obtained binding of perlecan was reached at 500RU. Binding of relevant antibodies to the 3 chips ascertained that the immobilised ligands were accessible at the surface, and that the antigenic structures recognised by relevant antibodies were preserved. These structures were therefore also regarded valid for studies of nucleosome interactions with the immobilised ligands.

Nucleosomes (Nuc and SN), DNA and antilaminin, anticollagen IV or antiperlecan antibodies were diluted twofold in running buffer from 500 nM (for nucleosomes, the concentration is given as mononucleosomes, defined as 200 kDa as the basic unit, while the concentration of DNA was calculated using 100 kDa for 200 bp) and injected over the surfaces with a flow rate of 5 μl/min for 900 s followed by injection of running buffer for 600 s. All responses were normalised and expressed relative to the baseline defined by the running buffer. Regeneration was performed with glycine‐HCl, pH 1.5 (CM5 chip) or pH 3.0 (SA chip), at 30 μl/min for 2 min. Values from the reference flow cell were subtracted from all sensorgrams.

Analysis of the sensorgrams was performed with the BIAcore T100 control software and BIAcore T100 evaluation software 1.1. The association (ka) and dissociation (kd) constants were determined, and KD was calculated, using the model for 1:1 ligand interaction.


Experimental validation of colocalisation TUNEL IEM for analyses in murine lupus nephritis

Control experiments and assay validation of TEM, IEM, colocalisation IEM and colocalisation TUNEL IEM, respectively, were performed on glomeruli of all mice included in this study, and are demonstrated in fig 11 for glomeruli of the nephritic mouse B/W15. TEM revealed mesangial and capillary membrane‐associated EDS (fig 1A1A),), and IEM demonstrated deposits of autoantibodies, perfectly localised within EDS (fig 1B1B).). Colocalisation IEM analyses revealed that the anti‐dsDNA 163p77 mAb and in vivo‐bound autoantibodies colocalised in structures constituting EDS (fig 1C1C),), confirming previous results on these kidneys.14 Antilaminin antibodies, on the other hand, bound glomerular membrane structures surrounding EDS (10 nm gold, fig 1D and 1E1E),), while autoantibodies bound EDS (5 nm gold), as shown by colocalisation IEM (fig 1E1E).). By colocalisation TUNEL IEM, autoantibodies were detected in EDS that contained material stained by the TUNEL assay (fig 1F1F).). DNase 1 treatment prior to TUNEL assay resulted in increased labelling of chromatin in EDS (fig 1G1G),), but did not uncover further extracellular chromatin (not shown). Colocalisation TUNEL IEM assay in absence of TdT resulted in detection of autoantibodies, while antibiotin antibodies and PAG‐10nm gold conjugate did not bind non‐specifically (fig 1H1H).). These data indicate that murine and human lupus nephritis have a common genesis placing nucleosomes as a key element in both.26

figure ar70482.f1
Figure 1 Validation of assays aimed at detection of glomerular deposits of autoantibodies and extracellular chromatin in nephritic B/W kidney sections by TEM, IEM, colocalisation IEM and colocalisation TUNEL IEM. TEM (A) and IEM (B) analyses revealed ...

Analyses of serum antibodies to dsDNA and nucleosomes, and determination of glomerular antibody deposits and their colocalisation with TUNEL‐positive extracellular chromatin

Selected for the present studies are sera and kidneys from a control BALB/c mouse, from the 10‐week‐old non‐nephritic B/W52 mouse, or from 3 B/W mice producing antibodies to dsDNA and nucleosomes (B/W2, B/W15 or B/W16). Figure 2A–E demonstrate antibody titration at week 33 (end point) of BALB/c, B/W52, B/W2, B/W15, B/W16, respectively. The B/W2, B/W15 and B/W16 mice, but not BALB/c or B/W52, produced anti‐dsDNA and antinucleosome antibodies. Of these, B/W2 and B/W16, but not B/W15, had proteinuria.

figure ar70482.f2
Figure 2 ELISA for detection of serum antibodies to dsDNA and nucleosomes, and IEM and colocalisation TUNEL IEM analyses of kidney sections. Results of these analyses are presented for kidney sections of BALB/c (A,F,K), B/W52 (B,G,L), B/W2 (C,H,M), ...

IEM analyses of glomeruli of BALB/c and B/W52 revealed no autoantibody‐binding in the glomeruli (fig 2F,G2F,G,, respectively), consistent with their normal appearance without EDS. Glomeruli of the other mice (B/W2, B/W15 and B/W16) were characterised by accumulation of EDS in glomerular membranes, and antibody deposits were strictly confined to these EDS (fig 2H,I,J2H,I,J,, for B/W2, B/W15 and B/W16, respectively). Further details on glomerular pathology and apoptosis in these kidneys are presented in Kalaaji et al.14

Glomerular membranes of BALB/c and B/W52 did not contain TUNEL‐positive material (fig 2K,L2K,L for BALB/c and B/W52, respectively). Colocalisation TUNEL IEM applied to glomeruli of B/W2, B/W15 and B/W16 demonstrated the presence of TUNEL‐positive (10 nm gold) membrane‐associated EDS that were targeted in vivo by autoantibodies (5 nm gold) ((figsfigs 1F and 2N2N for B/W15, fig 2M,O2M,O for B/W2 and B/W16, respectively). DNase I digestion of the same samples showed increased labelling of chromatin in EDS within glomerular membranes but did not uncover further extracellular DNA (data not shown, exemplified in fig 1G1G for B/W15). Colocalisation TUNEL IEM performed in the absence of TdT resulted in detection of autoantibodies (5 nm gold), but not of biotinylated nucleotides, in EDS (fig 1H1H for B/W15). These results reveal that membrane‐associated EDS in nephritic glomeruli contain TUNEL‐positive DNA targeted by nephritogenic autoantibodies.

Binding of nucleosomes to immobilised glomerular laminin, collagen IV or perlecan

To understand why nucleosomes redistribute to glomerular capillary and mesangial matrix membranes, we tested binding of nucleosomes or purified DNA to three major membrane components, collagen IV, laminin and perlecan by SPR analyses.

Control liquid chromatography/mass spectrometry (LC/MS, nanoAquity (Waters, Milford, MA) and Q‐TOF Ultima global mass spectrometer (Micromass, Manchester, UK)) analyses of the ligands immobilised on Biacore chips demonstrated that the laminin preparation contained laminin β2 and also α1 chains, while HSPG was demonstrated to contain predominantly perlecan, and traces of laminin α1/β2/γ1. The recombinant collagen IV was pure according to SDS‐PAGE (data not shown).

Serial dilutions of Nuc, SN, DNA, and of antibodies to laminin, collagen IV or perlecan were injected over the chips with immobilised membrane components. The response values at steady states and the dose–response of the analytes are presented in fig 3A,B3A,B.. The sensorgrams of laminin or collagen IV chips demonstrated binding of Nuc and SN, but not of DNA (fig 3A3A).). The sensorgrams of perlecan showed no binding of Nuc or DNA, and only marginal binding of the artificial SN (fig 3A3A).). Antibodies to collagen IV, laminin and perlecan bound the ligands at relatively high affinities (KD<5.1×10−8, table 11,, fig 3B3B).). The differences in RU units between the antibodies reflect most probably the differences in the number of molecules immobilised on the chips and the numbers of determinants recognised by individual antibodies.

Table thumbnail
Table 1 Determination of affinity of nucleosomes and antibodies for glomerular collagen IV and laminin by surface plasmon resonance analysis

The ka, kd and KD values of Nuc‐ and SN‐binding to the collagen IV or laminin chips were calculated, and the results are listed in table 11.. In general, Nuc possessed a higher affinity for laminin (KD = 9.7×10−9) than for collagen IV (KD = 3.2×10−8), while Nuc possessed almost a 100‐fold higher affinity than SN for laminin (KD 0.966×10−8 M and KD 1.0×10−8 M, for Nuc and SN respectively). This difference may be caused by interaction with laminin by non‐histone proteins presented by Nuc that are absent in SN (see fig 3C3C for details). As Nuc did not bind perlecan, and the artificial SN demonstrated marginal binding to perlecan, affinities were not calculated for this ligand.

To test if laminin and collagen IV together influenced the binding of Nuc, equimolar amounts of laminin and collagen IV were immobilised on the same chip (table 11).). The binding of Nuc to this chip was lower (KD = 1.8×10−8) compared with binding to chips presenting individual molecules. The affinities calculated for binding of individual antilaminin and anticollagen IV antibodies to the dually coated chip were also slightly lower than for the individually coated chips (table 11).


In this study, analyses were performed to determine the nature of glomerular, membrane‐associated EDS, and to determine why EDS associate with capillary and mesangial matrix membranes in lupus nephritis. The present results demonstrate that EDS contain nucleosomes and that these represent target structures for nephritogenic antibodies in vivo,6,14,27 and contradict the fact that nephritic, in vivo‐bound autoantibodies recognise glomerular, non‐nucleosomal antigens like laminin, collagen or α‐actinin.9,10,11,12,15 Furthermore, we provide evidence that nucleosomes are redistributed to glomerular membranes due to a high affinity at least for glomerular laminin and collagen IV. This explains the distinct membrane‐associated localisation of extracellular chromatin particles, and corresponding autoantibody deposits confined to these structures.

Dual specificity of anti‐DNA antibodies for several inherent glomerular constituents have been reported.11,28,29,30,31,32,33,34 There is, however, no firm information as to the nature of the glomerular target structures that de facto have bound these antibodies in vivo, whether nucleosomes,35 laminin,28 or, for example, α‐actinin31,32 or other antigens.

We have recently provided new information that may help solve this problem. With IEM, Kalaaji et al demonstrated that glomerular autoantibody deposits are associated with EDS characteristic of nephritic glomerular membranes.14 Furthermore, experimental antibodies to dsDNA, histones and transcription factors colocalised with in vivo‐bound autoantibodies in EDS in capillary and mesangial matrix membranes.14 The localisation of membrane components like collagen IV and laminin were distributed around the EDS, and α‐actinin was not a distinct part of EDS.13 This is consistent with observations that HSPG, laminin and collagen IV are not part of EDS in immune complex glomerulonephritis, as described by Moss et al36 and Haramoto et al.37 However, if membrane constituents bind nucleosomes, they formally participate in the structures that phenomenologically are observed as EDS with EM, while still nucleosomes represent targets for nephritic antibodies.

Because of the need for new therapy modalities for lupus nephritis, the decision was made to obtain data that conclusively define the nature of EDS that are targeted by nephritic antibodies in vivo. We therefore developed the colocalisation TUNEL IEM assay. Results clearly demonstrated that membrane‐associated EDS contain TUNEL‐positive DNA in the form of nucleosomes, and that these structures are targeted by nephritic autoantibodies in vivo. These data validate and confirm the less reliable data obtained in colocalisation IEM using potentially cross‐reactive experimental monoclonal antichromatin antibodies (data summarised in table 22).). Since the present results are similar to those obtained in human lupus nephritis,26 they validate the murine lupus nephritis model for further studies on the basic nature of human lupus nephritis.

Table thumbnail
Table 2 Summary of results of experiments addressed to determine the nature of electron dense structures associated with glomerular membranes in nephritic kidneys that are targeted by autoantibodies in vivo

Whether nucleosomes are trapped in glomerular membranes, like fish in a net, or inherit particular affinities for glomerular components has not been determined previously. DNA itself has been shown to have an affinity for collagen and collagen‐like structures in glomerular membranes,38 although we could not confirm this in our SPR analyses. Since DNA in vivo is present in the nucleosomal form, the binding properties of nucleosomes for glomerular membranes, for example, may be totally different from those of DNA. Berden and his group have investigated the basis for in vivo binding of anti‐DNA antibodies to glomerular membranes. They observed that anti‐DNA antibodies in complex with nucleosomes bound glomerular membranes and proposed that the binding was due to interaction of positively charged C‐ and N‐terminal histone tails with negatively charged residues on agrin or collagen IV, for example.6,35,39,40 This has also been discussed by Lefkowith and colleagues.7,27,41

In this study, we investigated whether nucleosomes have an affinity for the main components of glomerular membranes by SPR. For these analyses, we used nucleosomes stripped for non‐histone proteins, and nucleosomes generated by micrococcal nuclease digestion of chromatin,22 with structures and a size distribution similar to apoptotic nucleosomes as they appear in the context of apoptosis.

From SPR analyses, we observed binding of nucleosomes to the glomerular membrane components laminin and collagen IV, but not to perlecan. The results demonstrated furthermore that nucleosomes bind laminin and collagen IV with affinities equivalent to those of the control antibodies to laminin or collagen IV (see table 11 for details). For the calculations of ka and kd for nucleosome binding, we used the model for 1:1 ligand interaction. The observed curves gave a good fit with this model and allowed us to determine relative affinity differences between the analytes.

That nucleosomes did not bind perlecan was somewhat surprising, since perlecan have up to 4 HS chains,43 and cationic N‐terminal histone tails are assumed to bind to anionic HS in the glomerular basement membranes. Indeed, Kramers et al35 and Berden et al40 have demonstrated that the removal of HS chains from agrin can prevent binding of nucleosomes. The HSPG preparation used in these SPR analyses was prepared from Engelbreth–Holm–Swarm sarcoma cells and was demonstrated to contain predominantly perlecan heparan sulfate. Perlecan heparan sulfate is abundant in the glomerular mesangial matrix.44 Glomerular extracellular nucleosomes are also located in the mesangial matrix, but the data from the SPR analyses indicate that perlecan is not the membrane structure that binds chromatin. It will be interesting to determine whether agrin differs from perlecan in the ability to bind nucleosomes, since agrin is the most abundant HSPG in capillary membranes, and chromatin particles are also associated in these membranes. Nevertheless, it is quite clear from the present results that chromatin particles bind glomerular membranes at least through their high affinity for glomerular laminin and collagen.

The generation of nucleosomes in vivo requires apoptosis,40 and the disordered regulation of both apoptosis and the clearance of apoptotic products has been proposed to be implicated in the pathogenesis of SLE and lupus nephritis.45,46,47 An early event in lupus nephritis may therefore be the release of apoptotic nucleosomes that may bind components of glomerular membranes at high affinity. It is imperative in the context of present and previous results to analyse the factors that affect apoptosis in SLE.


This project has been financed by grants from the Norwegian Foundation for Health and Rehabilitation through the Norwegian Rheumatology Organization, by the Milieu Support given to OPR from the University of Tromsø and by grants from Northern Norway Regional Health Authority Medical Research Program. We thank Randi Olsen, Department of Electron Microscopy, IMB, University of Tromsø, for excellent technical assistance. Dr Tony Marion generously gave us the 163p77 anti‐DNA mAb. Dr Rufus Burlingame kindly provided us with stripped nucleosomes. We thank Manar Kalaaji for providing us with ELISA data on sera and the kidneys necessary for this study.


EDS - electron‐dense structures

GBM - glomerular basement membrane

HSPG - heparan sulfate proteoglycan

IEM - immune electron microscopy

mAb - monoclonal antibodies

Nuc - nucleosomes

SLE - systemic lupus erythematosus

SN - stripped nucleosomes

SPR - surface plasmon resonance

TEM - transmission electron microscopy

TUNEL - terminal transferase biotin‐dUTP nicked end‐labelling


Competing interests: None declared.


1. Hahn B H. Antibodies to DNA. N Engl J Med 1998. 3381359–1368.1368 [PubMed]
2. Tan E M, Cohen A S, Fries J F, Masi A T, McShane D J, Rothfield N F. et al The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982. 251271–1277.1277 [PubMed]
3. Isenberg D A, Ravirajan C T, Rahman A, Kalsi J. The role of antibodies to DNA in systemic lupus erythematosus—a review and introduction to an international workshop on DNA antibodies held in London, May 1996. Lupus 1997. 6290–304.304 [PubMed]
4. Haugbro K, Nossent J C, Winkler T, Figenschau Y, Rekvig O P. Anti‐dsDNA antibodies and disease classification in antinuclear antibody positive patients: the role of analytical diversity. Ann Rheum Dis 2004. 63386–394.394 [PMC free article] [PubMed]
5. Balow J E, Boumpas D T, Austin III H A. Systemic lupus erythematosus and the kidney. In: Lahita RG, ed. Systemic lupus erythematosus. 4th ed. New York: Elsevier Academic Press, 2004. 877–912.912
6. Berden J H M, Licht R, van Bruggen M C J, Tax W J M. Role of nucleosomes for induction and glomerular binding of autoantibodies in lupus nephritis. Curr Opin Nephrol Hypertens 1999. 8299–306.306 [PubMed]
7. Lefkowith J B, Gilkeson G S. Nephritogenic autoantibodies in lupus: current concepts and continuing controversies. Arthritis Rheum 1996. 39894–903.903 [PubMed]
8. Rekvig O P, Kalaaji M, Nossent H. Anti‐DNA antibody subpopulations and lupus nephritis. Autoimmun Rev 2004. 31–6.6 [PubMed]
9. Qureshi F, Yang Y, Jaques S M, Johnson M P, Naparstek Y, Ulmansky R. et al Anti‐DNA antibodies cross‐reacting with laminin inhibit trophoblast attachment and migration: implications for recurrent pregnancy loss in SLE patients. Am J Reprod Immunol 2000. 44136–142.142 [PubMed]
10. Mageed R A, Zack D J. Cross‐reactivity and pathogenicity of anti‐DNA autoantibodies in systemic lupus erythematosus. Lupus 2002. 11783–786.786 [PubMed]
11. Zhao Z, Weinstein E, Tuzova M, Davidson A, Mundel P, Marambio P. et al Cross‐reactivity of human lupus anti‐DNA antibodies with alpha‐actinin and nephritogenic potential. Arthritis Rheum 2005. 52522–530.530 [PubMed]
12. Sabbaga J, Line S R, Potocnjak P, Madaio M P. A murine nephritogenic monoclonal anti‐DNA autoantibody binds directly to mouse laminin, the major non‐collagenous protein component of the glomerular basement membrane. Eur J Immunol 1989. 19137–143.143 [PubMed]
13. Kalaaji M, Sturfelt G, Mjelle J E, Nossent H, Rekvig O P. Critical comparative analyses of anti‐alpha‐actinin and glomerulus‐bound antibodies in human and murine lupus nephritis. Arthritis Rheum 2006. 54914–926.926 [PubMed]
14. Kalaaji M, Mortensen E, Jorgensen L, Olsen R, Rekvig O P. Nephritogenic lupus antibodies recognize glomerular basement membrane‐associated chromatin fragments released from apoptotic intraglomerular cells. Am J Pathol 2006. 1681779–1792.1792 [PubMed]
15. Lafer E M, Rauch J, Andrzejewski C, Jr, Mudd D, Furie B, Furie B. et al Polyspecific monoclonal lupus autoantibodies reactive with both polynucleotides and phospholipids. J Exp Med 1981. 153897–909.909 [PMC free article] [PubMed]
16. Ben‐Bassat M, Rosenfeld J, Joshua H, Hazaz B, Gura V. Lupus nephritis. Electron‐dense and immunofluorescent deposits and their correlation with proteinuria and renal function. Am J Clin Pathol 1979. 72186–193.193 [PubMed]
17. Comerford F R, Cohen A S, Desai R G. The evolution of the glomerular lesion in NZB mice. A light and electron microscopic study. Lab Invest 1968. 19643–651.651 [PubMed]
18. Dillard M G, Tillman R L, Sampson C C. Lupus nephritis. Correlations between the clinical course and presence of electron‐dense deposits. Lab Invest 1975. 32261–269.269 [PubMed]
19. Bendiksen S, Van Ghelue M, Winkler T, Moens U, Rekvig O P. Autoimmunity to DNA and nucleosomes in binary tetracycline‐regulated polyomavirus T‐ag transgenic mice. J Immunol 2004. 1737630–7640.7640 [PubMed]
20. Hassell J R, Leyshon W C, Ledbetter S R, Tyree B, Suzuki S, Kato M. et al Isolation of two forms of basement membrane proteoglycans. J Biol Chem 1985. 2608098–8105.8105 [PubMed]
21. Andreassen K, Bendiksen S, Kjeldsen E, Van Ghelue M, Moens U, Arnesen E. et al T cell autoimmunity to histones and nucleosomes is a latent property of the normal immune system. Arthritis Rheum 2002. 461270–1281.1281 [PubMed]
22. Andreassen K, Bredholt G, Moens U, Bendiksen S, Kauric G, Rekvig O P. T cell lines specific for polyomavirus T‐antigen recognize T‐antigen complexed with nucleosomes: a molecular basis for anti‐DNA antibody production. Eur J Immunol 1999. 292715–2728.2728 [PubMed]
23. Fredriksen K, Osei A, Sundsfjord A, Traavik T, Rekvig O P. On the biological origin of anti‐double‐stranded (ds) DNA antibodies: systemic lupus erythematosus‐related anti‐dsDNA antibodies are induced by polyomavirus BK in lupus‐prone (NZB×NZW) F1 hybrids, but not in normal mice. Eur J Immunol 1994. 2466–70.70 [PubMed]
24. Rekvig O P, Moens U, Sundsfjord A, Bredholt G, Osei A, Haaheim H. et al Experimental expression in mice and spontaneous expression in human SLE of polyomavirus T‐antigen. A molecular basis for induction of antibodies to DNA and eukaryotic transcription factors. J Clin Invest 1997. 992045–2054.2054 [PMC free article] [PubMed]
25. Migheli A, Attanasio A, Schiffer D. Ultrastructural detection of DNA strand breaks in apoptotic neural cells by in situ end‐labelling techniques. J Pathol 1995. 17627–35.35 [PubMed]
26. Kalaaji M, Fenton K A, Mortensen E S, Olsen R, Sturfelt G, Alm P. et al Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. Kidney Int 2007. 71664–672.672 [PubMed]
27. Lefkowith J B, Kiehl M, Rubenstein J, DiValerio R, Bernstein K, Kahl L. et al Heterogeneity and clinical significance of glomerular‐binding antibodies in systemic lupus erythematosus. J Clin Invest 1996. 981373–1380.1380 [PMC free article] [PubMed]
28. Xie C, Liang Z, Chang S, Mohan C. Use of a novel elution regimen reveals the dominance of polyreactive antinuclear autoantibodies in lupus kidneys. Arthritis Rheum 2003. 482343–2352.2352 [PubMed]
29. Raz E, Brezis M, Rosenmann E, Eilat D. Anti‐DNA antibodies bind directly to renal antigens and induce kidney dysfunction in the isolated perfused rat kidney. J Immunol 1989. 1423076–3082.3082 [PubMed]
30. D'Andrea D M, Coupaye‐Gerard B, Kleyman T R, Foster M H, Madaio M P. Lupus autoantibodies interact directly with distinct glomerular and vascular cell surface antigens. Kidney Int 1996. 491214–1221.1221 [PubMed]
31. Mostoslavsky G, Fischel R, Yachimovich N, Yarkoni Y, Rosenmann E, Monestier M. et al Lupus anti‐DNA autoantibodies cross‐react with a glomerular structural protein: a case for tissue injury by molecular mimicry. Eur J Immunol 2001. 311221–1227.1227 [PubMed]
32. Deocharan B, Qing X, Lichauco J, Putterman C. Alpha‐actinin is a cross‐reactive renal target for pathogenic anti‐DNA antibodies. J Immunol 2002. 1683072–3078.3078 [PubMed]
33. Termaat R M, Assmann K J, van Son J P, Dijkman H B, Koene R A, Berden J H. Antigen‐specificity of antibodies bound to glomeruli of mice with systemic lupus erythematosus‐like syndromes. Lab Invest 1993. 68164–173.173 [PubMed]
34. Amital H, Heilweil M, Ulmansky R, Szafer F, Bar‐Tana R, Morel L. et al Treatment with a laminin‐derived peptide suppresses lupus nephritis. J Immunol 2005. 1755516–5523.5523 [PubMed]
35. Kramers C, Hylkema M N, van Bruggen M C, van de Lagemaat R, Dijkman H B, Assmann K J. et al Anti‐nucleosome antibodies complexed to nucleosomal antigens show anti‐DNA reactivity and bind to rat glomerular basement membrane in vivo. J Clin Invest 1994. 94568–577.577 [PMC free article] [PubMed]
36. Moss J, Woodrow D F, Shore I, Gower P, Phillips M, Spiro R G. Ultrastructural immunogold studies of heparan sulphate proteoglycan in normal human glomeruli and glomerulonephritis. J Pathol 1990. 161137–143.143 [PubMed]
37. Haramoto T, Makino H, Ikeda S, Wieslander J, Ota Z. Ultrastructural localization of the three major basement membrane components—type IV collagen, heparan sulfate proteoglycan and laminin—in human membranous glomerulonephritis. Am J Nephrol 1994. 1430–36.36 [PubMed]
38. Izui S, Lambert P H, Miescher P A. In vitro demonstration of a particular affinity of glomerular basement membrane and collagen for DNA. A possible basis for a local formation of DNA–anti‐DNA complexes in systemic lupus erythematosus. J Exp Med 1976. 144428–443.443 [PMC free article] [PubMed]
39. Berden J H M, van Bruggen M C J. Nucleosomes and the pathogenesis of lupus nephritis. Kidney & Blood Pressure Research 1997. 20198–200.200 [PubMed]
40. Berden J H, Grootscholten C, Jurgen W C, van der Vlag J. Lupus nephritis: a nucleosome waste disposal defect? J Nephrol. 2002;15(Suppl 6)S1–10.10
41. Bernstein K A, Valerio R D, Lefkowith J B. Glomerular binding activity in MRL lpr serum consists of antibodies that bind to a DNA/histone/type IV collagen complex. J Immunol 1995. 1542424–2433.2433 [PubMed]
42. van Bruggen M C, Kramers C, Walgreen B, Elema J D, Kallenberg C G, Van Den Born J. et al Nucleosomes and histones are present in glomerular deposits in human lupus nephritis. Nephrol Dial Transplant 1997. 1257–66.66 [PubMed]
43. Knox S M, Whitelock J M. Perlecan: how does one molecule do so many things? Cell Mol Life Sci 2006. 632435–2445.2445 [PubMed]
44. Raats C J, Van Den Born J, Berden J H. Glomerular heparan sulfate alterations: mechanisms and relevance for proteinuria. Kidney Int 2000. 57385–400.400 [PubMed]
45. Kamradt T, Mitchison N A. Tolerance and autoimmunity. N Engl J Med 2001. 344655–664.664 [PubMed]
46. Gaipl U S, Kuhn A, Sheriff A, Munoz L E, Franz S, Voll R E. et al Clearance of apoptotic cells in human SLE. Curr Dir Autoimmun 2006. 9173–187.187 [PubMed]
47. Berden J H. Lupus nephritis: consequence of disturbed removal of apoptotic cells? Neth J Med 2003. 61233–238.238 [PubMed]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group